Treatment choice in IPF
Research type
Research Study
Full title
IDENTIFICATION OF FACTORS INFLUENCING PATIENT CHOICE OF ANTIFIBROTIC TREATMENT IN IDIOPATHIC PULMONARY FIBROSIS
IRAS ID
256370
Contact name
Sherwood Burge
Contact email
Sponsor organisation
University Hospitals Birmingham NHS Foundation Trust
Duration of Study in the UK
1 years, 1 months, 0 days
Research summary
There are two licenced drugs for the treatment of idiopathic pulmonary fibrosis available on the NHS. We think that they are equally effective at reducing the progression of fibrosis. There a few patients, particularly those taking anticoagulants, where pirfenidone is the medication of choice. Most patients can choose which medication they receive. They have different side effects, which can nearly always be managed by dose adjustment or with additional treatments. After giving patients literature on both drugs we would like to find out what influences the patients treatment choice by administering a short self-completed questionnaire.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
19/WM/0231
Date of REC Opinion
19 Jul 2019
REC opinion
Favourable Opinion